Skip to main content

Specialty Pharmacy

  • Actavis realigns corporate structure

    DUBLIN — Actavis on Friday announced a realignment of its global strategic business structure to maximize the company's newly strengthened position as a leading specialty pharmaceutical developer, manufacturer and marketer, and to enhance Actavis' position for continued long-term growth. 

  • Frost & Sullivan: Global biosimilars space to reach $24 billion by 2019

    LONDON — The imminent entry of several companies — including big pharma, small biotech and generic participants — into the global biosimilars space will propel the market toward exponential growth. The market is expected to soar from $1.2 billion in 2013 to $24 billion in 2019, reported Frost & Sullivan in research released earlier this week. 

  • Diplomat partners on concert series to benefit employees, community

    FLINT, Mich. — Diplomat Pharmacy on Thursday announced that it will be partnering with The Whiting, Flint’s premier performing arts venue on bringing new entertainment opportunities to the area through the Gen X Concert Series. Performers featured will be targeted to “Generation X," or those born in the early 1960s through the early 1980s.

    In addition to the concert series, the partnership also will bring entertainment to Diplomat’s corporate headquarters. The Whiting will present local performers during select lunch periods for employees to enjoy.

  • Diplomat launches online specialty pharmacy resource targeting both patients and clinicians

    FLINT, Mich. — A new web platform has gone live from Diplomat, the nation’s largest independent specialty pharmacy reported Thursday. On Jan. 29 the company revealed a completely redesigned site that is "mobile-friendly, easy to use and primed for upcoming changes."

  • Cardinal Health posts Q2 revenues of $22.2 billion, increases outlook for fiscal year

    DUBLIN, Ohio — The loss of the Walgreens contract was a key consideration in Cardinal Health's 12% decline in overall revenue for the company's second quarter 2014, George Barrett, Cardinal Health chairman and CEO, told analysts Thursday morning. Revenue totaled $22.2 billion. The loss of the Walgreens contract totaled $5 billion. 

    But Cardinal Health is bullish regarding its future. Cardinal Health increased its outlook for the next six months, raising its non-GAAP EPS range to $3.75 to $3.85. 

  • Teva approved for new dose of Copaxone

    JERUSALEM — Teva Pharmaceutical Industries on Tuesday announced that the Food and Drug Administration approved its supplemental new drug application for three-times-a-week Copaxone in 40mg/mL. Daily Copaxone in 20mg/mL dosage will continue to be available.  

    Copaxone is administered to patients with relapsing forms of multiple sclerosis. The new formulation will allow for a less frequent dosing regimen.

  • Report: Specialty pharmacy to account for half of all prescription revenue by 2018

    PHILADELPHIA — Almost two-thirds of specialty pharmacy revenues are attributed to 1-of-3 companies, and the specialty pharmacy market is poised to explode, according to a Drug Channels Institute report released Tuesday. 

  • Hamacher Resource Group to hold workshop again in March

    WAUKESHA, Wis. — Hamacher Resource Group has announced that is offering its workshop, How to Grow Sales Within Independent Pharmacy, again on March 6 at its headquarters in Waukesha, Wis.

X
This ad will auto-close in 10 seconds